Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options

(2015) Susan Cornell   Therapeutics and Clinical Risk Management

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

(2014) Rury R. Holman et al.   AMERICAN HEART JOURNAL

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

(2014) Kazufumi Nakamura et al.   Cardiovascular Diabetology

On the potential of acarbose to reduce cardiovascular disease

(2014) Eberhard Standl et al.   Cardiovascular Diabetology

Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database

(2014) Jianping Weng et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin

(2014) Mitsuyoshi Takahara et al.   ENDOCRINE JOURNAL

Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes

(2014) Shashank R Joshi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis

(2014) Y. Li et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study

(2014) Mi Young Lee et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients

(2014) Guang Wang et al.   PLoS One

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients

(2014) Natsuyo Hariya et al.   Drugs in research & development

Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

(2014) Po-Hsun Chen et al.   Diabetology & Metabolic Syndrome

Results from a dietary survey in an Indian T2DM population: a STARCH study

(2014) Shashank R Joshi et al.   BMJ Open

Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus

(2014) Isabel Moreno-Indias et al.   Frontiers in Microbiology

Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis

(2013) Jorge L. Gross   ANNALS OF INTERNAL MEDICINE

Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

(2013) Ronald C.W. Ma et al.   Annals of the New York Academy of Sciences

Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report

(2013) Miao-yan Zheng et al.   Cardiovascular Diabetology

Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic Meta-analysis

(2013) Qibo Zhu et al.   CLINICAL THERAPEUTICS

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

A Prospective, Randomized, Open-Label Study Comparing the Efficacy and Safety of Preprandial and Prandial Insulin in Combination with Acarbose in Elderly, Insulin-Requiring Patients with Type 2 Diabetes Mellitus

(2013) Guang Yang et al.   Diabetes Technology & Therapeutics

MECHANISMS IN ENDOCRINOLOGY: Pathogenesis of type 2 diabetes in South Asians

(2013) Leontine E H Bakker et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Gut metagenome in European women with normal, impaired and diabetic glucose control

(2013) Fredrik H. Karlsson et al.   NATURE

Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes

(2013) Hitoshi Sugihara et al.   Journal of Diabetes Investigation

Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial

(2013) Wenying Yang et al.   Lancet Diabetes & Endocrinology

Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Early Improvement in Carotid Plaque Echogenicity by Acarbose in Patients With Acute Coronary Syndromes

(2012) Mitsumasa Hirano et al.   CIRCULATION JOURNAL

Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review

(2012) Giuseppe Derosa et al.   CLINICAL THERAPEUTICS

Transcultural Diabetes Nutrition Therapy Algorithm: The Asian Indian Application

(2012) Shashank R. Joshi et al.   Current Diabetes Reports

Alpha-glucosidase inhibitors 2012 – cardiovascular considerations and trial evaluation

(2012) Eberhard Standl et al.   Diabetes & Vascular Disease Research

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Differential Effects of α-Glucosidase Inhibitors on Postprandial Plasma Glucose and Lipid Profile in Patients with Type 2 Diabetes Under Control with Insulin Lispro Mix 50/50

(2012) Tomoko Kimura et al.   Diabetes Technology & Therapeutics

Miglitol, α-glycosidase inhibitor, reduces visceral fat accumulation and cardiovascular risk factors in subjects with the metabolic syndrome: A randomized comparable study

(2012) Michio Shimabukuro et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension

(2012) Markolf Hanefeld et al.   JOURNAL OF HYPERTENSION

Functional interactions between the gut microbiota and host metabolism

(2012) Valentina Tremaroli et al.   NATURE

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes

(2012) Miyako Kishimoto et al.   Diabetes Therapy

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

(2012) Christoph Rosak et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin

(2011) Kazutaka Aoki et al.   ACTA DIABETOLOGICA

Effect of 3-Month Repeated Administration of Miglitol on Vascular Endothelial Function in Patients With Diabetes Mellitus and Coronary Artery Disease

(2011) Takuo Emoto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

(2011) J. J. Holst et al.   DIABETES CARE

Globalization of Diabetes: The role of diet, lifestyle, and genes

(2011) F. B. Hu   DIABETES CARE

The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus

(2011) R. S. Kootte et al.   DIABETES OBESITY & METABOLISM

Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes

(2011) Mi K. Kim et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: An Asian-Pacific perspective and expert recommendations

(2011) Wayne H.-H. Sheu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of Acarbose, an Alpha-Glucosidase Inhibitor, on Serum Lipoprotein Lipase Mass Levels and Common Carotid Artery Intima-Media Thickness in Type 2 Diabetes Mellitus Treated by Sulfonylurea

(2011) Tomokazu Oyama et al.   Journal of Atherosclerosis and Thrombosis

Weight Beneficial Treatments for Type 2 Diabetes

(2011) L. F. Meneghini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data

(2011) Shi-Dou Lin et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea

(2011) Seung-Hyun Ko et al.   Diabetes & Metabolism Journal

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

(2010) Sheng-Hwu Hsieh et al.   ACTA DIABETOLOGICA

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

(2010) Toru Kato et al.   Cardiovascular Diabetology

Single Administration of α-Glucosidase Inhibitors on Endothelial Function and Incretin Secretion in Diabetic Patients With Coronary Artery Disease

(2010) Makoto Hiki et al.   CIRCULATION JOURNAL

Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease

(2010) Masayoshi Koyasu et al.   CLINICAL THERAPEUTICS

Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes

(2010) A. Sinha et al.   DIABETES CARE

Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h Plasma Glucose Levels Within a Normoglycemic Range

(2010) F. Ning et al.   DIABETES CARE

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

(2010) Y. Iwamoto et al.   DIABETES OBESITY & METABOLISM

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load

(2010) Giuseppe Derosa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Nitric oxide – the endothelium-derived relaxing factor and its role in endothelial functions

(2010) V. Bauer et al.   GENERAL PHYSIOLOGY AND BIOPHYSICS

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus

(2010) Takeshi Osonoi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus

(2010) Hiroyasu Uzui et al.   Journal of Diabetes Investigation

Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients

(2009) Mihoko Matsumura et al.   ADVANCES IN THERAPY

Postprandial hyperglycemia as an etiological factor in vascular failure

(2009) Koichi Node et al.   Cardiovascular Diabetology

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial

(2009) Giuseppe Derosa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Target for Glycemic Control: Concentrating on glucose

(2009) L. Monnier et al.   DIABETES CARE

Are the effects ofα-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?

(2009) Yoshihiko Suzuki et al.   FEBS LETTERS

Diabetes in Asia

(2009) Juliana C. N. Chan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance

(2009) Ryuzo Kawamori et al.   LANCET

Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients

(2008) Mayumi Negishi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

(2008) C. Pan et al.   DIABETIC MEDICINE

Effects of the Alpha Glucosidase Inhibitor Acarbose on Endothelial Function after a Mixed Meal in Newly Diagnosed Type 2 Diabetes

(2008) F. Pistrosch et al.   HORMONE AND METABOLIC RESEARCH

Incretin-Based Therapies in Type 2 Diabetes Mellitus

(2008) Chee W. Chia et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance

(2008) Sizuo Kajiyama et al.   NUTRITION RESEARCH